China has overhauled its stem cell regulatory framework since 2021. Understanding the new NMPA rules is essential for any patient considering treatment in China.
China's approach to regulating stem cell therapies has undergone a fundamental transformation over the past decade. Understanding this evolution is essential for international patients seeking to distinguish legitimate, evidence-based treatment from the unregulated clinics that once proliferated — and in some cases still operate.
China's Stem Cell Regulatory Evolution
China's approach to regulating stem cell therapies has undergone a fundamental transformation over the past decade. Understanding this evolution is essential for international patients seeking to distinguish legitimate, evidence-based treatment from the unregulated clinics that once proliferated — and in some cases still operate.
The Pre-2015 "Wild West" Era
Prior to 2015, China had no specific regulatory framework for stem cell therapies. Hundreds of clinics offered stem cell treatments commercially without clinical trial data or regulatory oversight. A landmark 2012 investigation published in Cell Stem Cell documented 23 clinics offering unproven stem cell treatments to foreign patients, many making unsubstantiated efficacy claims.
This era is largely over, but its legacy continues to taint perceptions of Chinese stem cell medicine — and some unregulated providers unfortunately still operate in gray areas.
The 2015–2019 Framework: Clinical Research Classification
In 2015, the National Health Commission (NHC) and NMPA jointly issued the "Administrative Measures for Clinical Research of Stem Cells," establishing the "hospital-based clinical research" category for stem cell projects. This allowed hospitals to conduct stem cell research under institutional review board oversight, distinct from formal drug trials.
This framework had limitations — the absence of formal approval requirements and payment prohibition created ambiguity — but it represented China's first genuine attempt at stem cell-specific oversight.
The 2021–2023 Tightening: Drug Pathway Mandatory
A critical regulatory shift occurred in 2021. The NMPA issued updated guidance (Announcement No. 8, 2022) that effectively required all cell therapies with therapeutic claims to follow the formal drug approval pathway — the same Clinical Trial Application (IND) process used for conventional pharmaceuticals.
Key changes included:
- Mandatory IND filing for all clinical trials involving cell therapies
- GMP manufacturing requirements for all cells used in trials
- Prohibition on charging patients for unapproved investigational cell therapies
- Centralized registration of all trials in the CDE (Center for Drug Evaluation) system
As a result, the number of hospitals offering "commercial" stem cell treatments outside of formal trial frameworks dropped significantly. As of 2024, the NHC had approved 152 hospital-based stem cell research projects — a tightly controlled list.
2025: The First Commercial Approval
On January 2, 2025, the NMPA approved amimestrocel (Ruibosheng) for steroid-refractory aGVHD — the first commercially marketed stem cell drug in China. This approval signifies that China's regulatory pathway has matured to the point of issuing full marketing authorizations for cell therapies with sufficient clinical evidence.
The approval was granted under a "conditional approval" framework, requiring the manufacturer (Platinum Life) to submit additional post-market confirmatory data — analogous to the FDA's Accelerated Approval pathway.
How to Verify a Provider's Regulatory Status
International patients can verify the legitimacy of any Chinese stem cell provider through three official sources:
- CDE Clinical Trial Registry (chinadrugtrials.org.cn) — search by condition or institution to find registered trials
- NHC Approved Hospital Research Projects — the official list of 152 approved hospital-based stem cell research institutions
- NMPA Drug Database (nmpa.gov.cn) — search for approved cell therapy products
Any provider that cannot demonstrate their treatment falls into one of these three categories — approved drug, registered CDE trial, or approved NHC hospital research project — should be avoided.
What This Means Practically
For international patients, the post-2021 regulatory environment means:
- Fewer providers, but higher quality and accountability at those that remain
- Treatment within clinical trials generally carries no direct charge for the cell therapy itself
- Published trial data is increasingly available to review before making decisions
- The NMPA approval pathway provides a roadmap for more commercial approvals in coming years
Sources: NMPA Announcement No. 8, 2022 (nmpa.gov.cn); NHC Stem Cell Clinical Research Management Measures 2015; Cell Stem Cell Vol. 11, Issue 6, 2012; BioInformant Global Stem Cell Clinical Trial Report 2024.